Cytokine-activated natural killer (NK) cells derived from donated umbilical cord blood, combined with an investigational bispecific antibody targeting CD16a and CD30 known as AFM13, displayed potent anti-tumor activity against CD30+ lymphoma cells, according to a new preclinical study from researchers at The University of Texas MD Anderson Cancer Center.
The findings were published today in Clinical Cancer Research, a journal of...
The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) plays an important and previously unknown role in blocking a form of cell death...
The University of Texas MD Anderson Cancer Center and the Broad Institute of MIT and Harvard today announced the launch of a new translational...
Researchers at The University of Texas MD Anderson Cancer Center have developed a first-of-its-kind spatial atlas of early-stage lung cancer and surrounding normal lung tissue at single-cell resolution, providing a valuable resource for studying tumor development and identifying new therapeutic targets. The study was published today in Cancer Discovery, a journal of the American Association for Cancer Research.
The findings reveal...
A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy...
The University of Texas MD Anderson Cancer Center strongly endorses the Food and Drug Administration (FDA) plan to prohibit menthol cigarettes...
The University of Texas MD Anderson Cancer Center today announced efforts to advance its capabilities to seamlessly connect basic science,...
The American Society of Clinical Oncology (ASCO) today announced it will present three of its highest honors to faculty members from The University...
Sharon Dent, Ph.D., professor of Epigenetics and Molecular Carcinogenesis, and director of the Virginia Harris Cockrell Cancer Research Center...
The University of Texas MD Anderson Cancer Center and Boehringer Ingelheim today announced the extension and expansion of their joint Virtual...